Peer-reviewedLicence not statedFuture Oncology
Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma
- 1Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye
Related
- Exceptionally Durable Response to First-Line S-1 Monotherapy in Metastatic Pancreatic Adenocarcinoma: A Case Report
- Non-Invasive Assessment of SMAD4 Expression Status in Pancreatic Ductal Adenocarcinoma: Diagnostic Value of T1ρ-Weighted Imaging Combined with Clinical Parameters
- Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models
- Surufatinib and camrelizumab plus nab-paclitaxel–gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
- Staging laparoscopy for radiographically non-metastatic pancreatic ductal adenocarcinoma: cytology-driven upstaging and the SENDAI-SL risk-enrichment score
BibTeX
@article{yesilyurt2026combined,
title = {{Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma}},
author = {Berkay Yeşilyurt and Ismet Seven and Fahriye Tuğba Köş},
journal = {Future Oncology},
year = {2026},
month = sep,
doi = {10.1080/14796694.2026.2732589},
url = {https://doi.org/10.1080/14796694.2026.2732589},
}
RIS
TY - JOUR
TI - Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma
AU - Berkay Yeşilyurt
AU - Ismet Seven
AU - Fahriye Tuğba Köş
PY - 2026
DA - 2026/09/12
JO - Future Oncology
DO - 10.1080/14796694.2026.2732589
UR - https://doi.org/10.1080/14796694.2026.2732589
SN - 1479-6694
SN - 1744-8301
ER -